down arrow

Eledon Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28617K1016
USD
1.59
0.11 (7.43%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.571.67

52 Week

1.355.08
Valuation
Technical
Day's Volume

CASH

1.16 M

Shareholding (Jun 2025)

FII

6.18%

Held by 30 FIIs

DII

74.56%

Held by 17 DIIs

Promoter

6.72%

How big is Eledon Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Eledon Pharmaceuticals, Inc. has a market capitalization of 168.27 million and reported net sales of 0.00 million with a net profit of -41.60 million over the last four quarters. Shareholder's funds were 118.14 million, and total assets were 229.44 million.

As of Jun 18, Eledon Pharmaceuticals, Inc. has a market capitalization of 168.27 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, and a net profit of -41.60 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 118.14 million, while total assets were reported at 229.44 million.

Read More

What does Eledon Pharmaceuticals, Inc. do?

22-Jun-2025

Eledon Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $6 million and a market cap of $168.27 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -83.68%.

Overview: <BR>Eledon Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 168.27 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.09 <BR>Return on Equity: -83.68% <BR>Price to Book: 1.47<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Eledon Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Eledon Pharmaceuticals, Inc. is in a bearish trend, with negative indicators across multiple technical analyses and significant underperformance compared to the S&P 500.

As of 12 September 2025, the technical trend for Eledon Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Bollinger Bands are showing a mildly bearish trend on the weekly chart and bearish on the monthly chart. Additionally, the KST is bearish on the weekly timeframe and mildly bearish monthly. The Dow Theory confirms a mildly bearish outlook on both weekly and monthly bases. <BR><BR>In terms of performance, Eledon has underperformed the S&P 500 across multiple periods, with a year-to-date return of -38.11% compared to the S&P 500's 12.22%, and a 5-year return of -84.09% versus the S&P 500's 96.61%. Overall, the current technical stance is bearish, indicating weakness in the stock's performance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 154 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-99.75%

stock-summary
Price to Book

1.46

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.61%
0%
-38.61%
6 Months
-49.84%
0%
-49.84%
1 Year
-66.6%
0%
-66.6%
2 Years
39.47%
0%
39.47%
3 Years
-36.65%
0%
-36.65%
4 Years
-60.45%
0%
-60.45%
5 Years
-92.98%
0%
-92.98%

Eledon Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Eledon Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Eledon Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Bollinger Bands are showing a mildly bearish trend on the weekly chart and bearish on the monthly chart. Additionally, the KST is bearish on the weekly timeframe and mildly bearish monthly. The Dow Theory confirms a mildly bearish outlook on both weekly and monthly bases. In terms of performance, Eledon has underperformed the S&P 500 across multiple periods, with a year-to-date return of -38.11% compared to the S&P 500's 12.22%, and a 5-year return of -84.09% versus the S&P 500's 96.61%. Overall, the current technical stance is bearish, indicating weakness in the stock's performance....

Read More
Eledon Pharmaceuticals Hits New 52-Week Low at $2.31

Eledon Pharmaceuticals Hits New 52-Week Low at $2.31

Eledon Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a challenging year with a notable stock price decline. The company, operating in the Pharmaceuticals & Biotechnology industry, has a market capitalization of USD 154 million and exhibits significant financial strain, as indicated by its negative financial metrics.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-244.11%
EBIT to Interest (avg)
-39.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.09
Sales to Capital Employed (avg)
0
Tax Ratio
2.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.23%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.61
EV to EBIT
-0.77
EV to EBITDA
-0.77
EV to Capital Employed
-6.00
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-83.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 16 Schemes (12.54%)

Foreign Institutions

Held by 30 Foreign Institutions (6.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 75.06% vs -367.71% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.70",
          "val2": "-14.40",
          "chgp": "-71.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.30",
          "val2": "-31.30",
          "chgp": "139.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-44.90",
          "chgp": "75.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.93% vs -32.39% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.20",
          "val2": "-42.60",
          "chgp": "-64.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "30.90",
          "val2": "-76.20",
          "chgp": "140.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.20",
          "val2": "-116.50",
          "chgp": "68.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-24.70
-14.40
-71.53%
Interest
0.00
0.00
Exceptional Items
12.30
-31.30
139.30%
Consolidate Net Profit
-11.20
-44.90
75.06%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 75.06% vs -367.71% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-70.20
-42.60
-64.79%
Interest
0.00
0.00
Exceptional Items
30.90
-76.20
140.55%
Consolidate Net Profit
-36.20
-116.50
68.93%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.93% vs -32.39% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Eledon Pharmaceuticals, Inc. stock-summary
stock-summary
Eledon Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."